Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 5/20 | 0.59 |
| ▸ | PGK2 | P07205 | 5/20 | 0.59 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.51 |
| ▸ | GRM8 | O00222 | 2/20 | 0.51 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.51 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | PTPRC | P08575 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ACP3 | P15309 | 1/20 | 0.36 |
| ▸ | GRM6 | O15303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11208020 | 0.88 | PGK1 (0.71) | PGK1PGK2PTPN5PTPRCSRC | |
| SCHEMBL11079769 | 0.82 | PGK1 (0.59) | PGK1PGK2PTPN5MEN1KMT2A | |
| SCHEMBL744205 | 0.79 | SRC (0.60) | PGK1PGK2GRM4GRM8GRM7 | |
| SCHEMBL16931008 | 0.79 | ACP3 (0.57) | PGK1PGK2GRM4GRM8GRM7 | |
| SCHEMBL5743524 | 0.77 | PGK1 (0.59) | PGK1PGK2MEN1KMT2A | |
| SCHEMBL11080198 | 0.77 | PGK1 (0.59) | PGK1PGK2MEN1KMT2A | |
| SCHEMBL11078378 | 0.77 | PGK1 (0.59) | PGK1PGK2PTPN5MEN1KMT2A | |
| (4-Chlorophenyl)(Hydroxy)Methylphosphonic Acid SCHEMBL292744 | 0.77 | PGK1 (0.59) | PGK1PGK2PTPN5MAPT | |
| SCHEMBL11082211 | 0.77 | PGK1 (0.59) | PGK1PGK2PTPN5KMT2A | |
| (4-Chlorophenyl)(Hydroxy)Methylphosphonic Acid SCHEMBL5746553 | 0.77 | PGK1 (0.59) | PGK1PGK2PTPN5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170306157-A1 | Modified Colorants and Inkjet Ink Compositions Comprising Modified Colorants | CABOT CORP (US) | 2017-10-26 | — | — | US | disclosed |
| US-9732227-B2 | Modified colorants and inkjet ink compositions comprising modified colorants | CABOT CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| EP-3040382-A1 | MODIFIED COLORANTS AND INKJET INK COMPOSITIONS COMPRISING MODIFIED COLORANTS | Cabot Corporation (US) | 2016-07-06 | — | — | EP | disclosed |
| US-20160075880-A1 | Modified Colorants and Inkjet Ink Compositions Comprising Modified Colorants | CABOT CORPORATION | 2016-03-17 | — | — | US | disclosed |
| US-9096624-B2 | Amino pyrimidine anticancer compounds | OSI Pharmaceuticals, LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-8858695-B2 | Modified colorants and inkjet ink compositions comprising modified colorants | CABOT CORPORATION (US) | 2014-10-14 | — | — | US | disclosed |
| CN-101379143-B | Modified colorants and inkjet ink compositions comprising modified colorants | CABOT CORP | 2014-02-12 | — | — | CN | disclosed |
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2013-09-05 | — | — | US | disclosed |
| EP-2438056-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2012-04-11 | — | — | EP | disclosed |
| EP-2431426-A1 | Modified colorants and inkjet ink compositions comprising modified colorants | Cabot Corporation (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2431425-A1 | Modified colorants and inkjet ink compositions comprising modified colorants | Cabot Corporation (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2431427-A1 | Modified colorants and inkjet ink compositions comprising modified colorants | Cabot Corporation (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010141406-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| CN-101379143-A | Modified colorants and inkjet ink compositions comprising modified colorants | CABOT CORP (US) | 2009-03-04 | — | — | CN | disclosed |
| EP-1951821-A2 | MODIFIED COLORANTS AND INKJET INK COMPOSITIONS COMPRISING MODIFIED COLORANTS | Cabot Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007053564-A2 | MODIFIED COLORANTS AND INKJET INK COMPOSITIONS COMPRISING MODIFIED COLORANTS | CABOT CORPORATION (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070100024-A1 | Modified colorants and inkjet ink compositions comprising modified colorants | CABOT CORPORATION | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | PGK1 240/4885PGK2 245/4885GRM4 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.